Below you can find prescribing guidelines and their review dates.
Principles of shared care protocols and guidelines
Acromegaly - Review date on publication of NICE guidance
Amiodarone - Review date extended to January 2023
Azathioprine and Mercaptopurine in adults and young people over 16 years - July 2022
Bipolar disorder - February 2023
Cinacalcet - February 2026
Dalteparin - June 2021
Dementia - Prescribing of Cognitive Enhancers - April 2022
Denosumab (Prolia ®▼) - October 2022
DMARDs monitoring quick reference guide - Review date extended to February 2024
Please refer to individual shared care guidelines for more detailed information
Epilepsy in adults - April 2027
Epilepsy in children - September 2021
Growth hormone: The treatment of Adults with Growth Hormone (Somatropin) - Review date extended to March 2023
Growth hormone - Treatment of children with recombinant human growth hormone - February 2025
Hydroxychloroquine - January 2023
Hypertension – Community Pharmacy Led Hypertension Service - Review date extended to January 2024
Leflunomide - October 2025
Melatonin in the treatment of sleep disorders in children - September 2025
Methotrexate - June 2023
Midodrine - March 2027
Modafinil – February 2025
Mycophenolate - February 2026
Nebulised Colomycin®, gentamicin or tobramycin in adults with non-cystic fibrosis bronchiectasis - September 2026
Parkinson’s disease - November 2026
Prostatic Cancer - Hormonal Management of Prostatic Cancer – January 2021
Rifaxamin for Hepatic Encephalopathy - January 2024
Riluzole - August 2025
Sublingual Immunotherapy (SLIT) (Grazax®/Acarizax®) - For adults and children diagnosed with severe allergic rhinitis to grass pollen or house dust mite - February 2027
Sulfasalazine - Review date extended to November 2022
SSRIs in children and young people - June 2025
Topical testosterone replacement therapy in post-menopausal women- July 2026
Triptorelin for the treatment of Central Precocious Puberty in Children - February 2025